Revolution Medicines, Inc. Common Stock
RVMD
$180.70
-6.40%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel small-molecule therapies that bind directly to RAS variants — its RAS(ON) inhibitor platform targets RAS-addicted cancers historically considered undruggable, spanning monotherapy and combination approaches across pancreatic, colorectal, and lung cancer indications. The company has transitioned from a pure discovery-stage biotech into a commercial-stage organization following FDA approval of its lead asset Rasonque (daraxonrasib), positioning it as a first-mover in the RAS(ON) inhibitor class with a differentiated chemical-biology toolkit built on unconventional binding sites. The investor narrative has shifted decisively from clinical de-risking to commercial execution: a Phase 3 pancreatic cancer trial that roughly doubled survival versus chemotherapy, a rapid one-month FDA approval, and encouraging initial Rasonque uptake in Q3 results have driven a multi-hundred-percent re-rating, while a concurrent $2.2 billion upsized equity raise has funded the launch but introduced dilution. The debate now centers on whether peak sales estimates near $11.5 billion justify the current valuation, how durable Rasonque's first-in-class advantage is against larger oncology competitors, and whether the pipeline's combination strategies can extend the franchise beyond pancreatic cancer.…
RVMD
Revolution Medicines, Inc. Common Stock
$180.70
Related headlines
Investment Opinion: Should I buy RVMD Today?
Rating: Buy, but only as a staged, risk-sized position rather than a full allocation at $192.28. The thesis is that Rasonque's first-in-class RAS(ON) launch is real and inflecting — $197.56 million of product revenue in its first full quarter at a 99.83% gross margin — while 24 of 25 analysts rate the stock Buy with a $261.47 average target implying +36% upside; the constraint is that 198.16x EV/Sales already discounts much of that success, so the reward is asymmetric only if you buy weakness rather than chase the 8.24% single-day pop.
Four data points anchor the rating. First, valuation is extreme on trailing metrics (EV/Sales 198.16x, PB 18.37x versus 3.24x at year-end 2024) but far less so against consensus forward revenue of $8.47 billion and forward EPS of $15.77 — on those numbers the market is paying roughly 1.8x forward sales for a franchise analysts peg near $11.5 billion in peak sales. Second, the growth trajectory is a step-function, not a slope: revenue went from $0 in Q1 and Q2 2026 to $197.56 million in Q3, and the quarter beat both earnings and sales estimates. Third, profitability is inverted — gross margin of 99.83% coexists with a -206.2% net margin because R&D of $417.09 million and G&A of $153.29 million swamp gross profit, and trailing free cash flow is -$1.44 billion. Fourth, the balance sheet buys time: debt-to-equity of 0.097, a current ratio of 7.14, and roughly $2.2 billion raised in April 2026 mean no near-term financing cliff, though shares outstanding rose from 189.2 million to 214.9 million in a single quarter.
The rating would upgrade to a higher-conviction Buy on either a pullback toward the $177.96 October low (roughly -7%) or a Q4 print showing sequential Rasonque revenue growth above ~30% with stable pricing. It would downgrade to Hold if Q4 revenue stalls below $200 million, if gross margin slips materially from 99.83% (a sign of discounting or mix shift), or if a competitor discloses RAS(ON) data that narrows the first-in-class gap. The biggest risks are single-asset concentration (100% of revenue from one drug), a $1.44 billion annual cash burn that could force another dilutive raise, and multiple compression at 18.37x book. Verdict: overvalued on trailing multiples, arguably fairly valued to modestly undervalued on forward consensus — a high-quality franchise trading at a price that leaves little room for error.
Sign up to view all
RVMD 12-Month Price Forecast
The directional case is clearly bullish: a genuine launch inflection, a 99.83% gross margin that gives near-total operating leverage on incremental revenue, near-unanimous Street support, and a balance sheet that removes near-term financing risk. What tempers confidence is price and timing — at 198.16x trailing EV/Sales and 18.37x book, the stock has already re-rated more than 5x in a year and has stalled (-4.28% over one month, -6.27% over three months) below its $224.31 high, suggesting the easy money has been made. The wide $159 analyst target spread ($179 to $338) confirms that the magnitude of the outcome, not its direction, is the open question. I would upgrade to high confidence on a Q4 print showing strong sequential revenue growth with margins intact, or on a pullback toward the $177.96 October low that restores a margin of safety; I would downgrade to neutral on any sequential revenue decline, gross margin erosion, or credible competitive RAS(ON) data.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $274.84 and implied upside of +52.1% versus the current price.
Average Target
$274.84
25 analysts
Implied Upside
+52.1%
vs. current price
Analyst Count
25
covering this stock
Price Range
$179 - $350
Analyst target range
Coverage is exceptionally strong for a company of this profile: 24 analysts cover RVMD with a distribution of 24 Buy, 1 Hold, and 0 Sell, yielding a consensus recommendation of "strong_buy" and a recommendation mean of 1.28 (where 1.0 is a strong buy). The average target price of $261.47 implies roughly +36% upside from the current $192.28, a bullish signal that stands in contrast to the stock's recent 1-month and 3-month consolidation. The consensus is unambiguously bullish, and the recent institutional ratings flow confirms it — HC Wainwright, Truist, TD Cowen, Guggenheim, Piper Sandler, RBC, Evercore ISI, and Needham have all reiterated Buy/Outperform/Overweight ratings in October and November 2026, with no downgrades visible in the data. The target range spans $179.00 to $338.00 — a wide $159 spread that signals meaningful uncertainty about the magnitude of Rasonque's commercial success. The high target of $338.00 (roughly +76% upside) likely assumes aggressive peak-sales realization near or above the $11.5 billion analyst estimate, successful pipeline expansion into additional RAS-driven indications, and multiple expansion as the franchise proves durable. The low target of $179.00 (about -7% downside) likely prices in launch execution risk, competitive pressure from larger oncology players, and the dilution overhang from the $2.2 billion raise — notably, the low target sits just below the current price, suggesting even the most cautious analyst sees limited downside from here. The wide spread, combined with the 24-to-1 Buy/Hold ratio, indicates strong directional conviction but high dispersion on magnitude — typical of a binary, event-driven biotech where the range of outcomes hinges on commercial uptake curves and pipeline readouts rather than near-term earnings precision.
Bulls vs Bears: RVMD Investment Factors
The bull case currently rests on stronger hard evidence: a genuine launch inflection ($197.56 million in first-quarter product revenue from zero), a 99.83% gross margin, a fortress balance sheet, and near-unanimous Street support (24 Buy, 1 Hold, 0 Sell) with a $261.47 average target implying +36% upside. The bear case is not about the science or the launch but about price: at 198x EV/Sales and 18.37x book, the stock has already re-rated more than 5x and now discounts a multi-billion-dollar franchise, while losses widen (-$407.46 million in Q3) and cash burn runs at $1.44 billion annually. The single most important tension is whether Rasonque's sequential revenue ramp can compound fast enough to justify the forward consensus of $8.47 billion in revenue before dilution or competitive entry erodes the first-in-class premium. On balance the evidence favors the bulls directionally, but the margin of safety is thin, which argues for accumulation on weakness rather than chasing strength.
Bullish
- Launch inflection beats expectations: Q3 2026 delivered $197.56 million in product revenue versus $0 in Q1 and Q2 2026, the first full quarter of Rasonque commercialization, and the quarter beat both earnings and sales estimates on 'encouraging Rasonque uptake.' With gross margin at 99.83% (COGS of just $327,000), nearly every incremental revenue dollar drops to gross profit, so the ramp has unusually high operating leverage.
- Unanimous analyst conviction, 36% upside: 24 of 25 analysts rate RVMD Buy with zero Sells, a recommendation mean of 1.28 (strong buy), and an average target of $261.47 implying +36% upside from $192.28. Even the low target of $179.00 sits only about 7% below the current price, meaning the most cautious analyst on the Street sees limited downside from here.
- First-in-class RAS(ON) platform: Rasonque (daraxonrasib) is a first-mover in direct RAS(ON) inhibition, a class targeting cancers historically considered undruggable, and its Phase 3 pancreatic trial roughly doubled survival versus chemotherapy. The one-month FDA approval validates both the asset and the platform, which spans pancreatic, colorectal, and lung indications and provides optionality beyond a single product.
- Fortress balance sheet funds the launch: Debt-to-equity is just 0.097 and the current ratio is 7.14, and the company raised roughly $2.2 billion in upsized offerings in April 2026, leaving $631.74 million in cash plus substantial investment securities at Q3 end. That liquidity funds commercialization and pipeline expansion without near-term financing pressure, a rarity for a company burning $1.44 billion in trailing free cash flow.
Bearish
- Valuation prices in near-perfection: EV/Sales stands at 198.16x and the historical Q3 PS ratio at 223.32x, versus the 8-15x forward sales typical of commercial-stage oncology companies with blockbuster launches. The PB ratio has expanded from 3.24x at year-end 2024 to 9.28x at year-end 2025 to 18.37x in Q3 2026, placing the stock at the very top of its historical band and leaving multiple compression risk elevated if launch metrics disappoint.
- Losses widening despite revenue: Q3 net loss expanded to -$407.46 million from -$305.21 million a year earlier, and EBITDA deteriorated from -$289.44 million to -$373.05 million, as R&D of $417.09 million and G&A of $153.29 million swamp gross profit. Net margin is -206.2% and trailing free cash flow is -$1.44 billion, so the company consumes roughly $1.4 billion annually and depends on accelerating revenue or further raises.
- Single-asset concentration risk: 100% of the $197.56 million in Q3 revenue is product-based with no collaboration or licensing contribution, meaning the entire top line hinges on commercial execution of one drug. Any launch stumble, label restriction, or safety signal on Rasonque would hit the whole thesis at once, with no diversified revenue base to cushion the blow.
- Momentum has broken down: Despite a +213.26% one-year gain, the stock is down 4.28% over one month and 6.27% over three months, and its 3-month relative strength versus SPY is -1.36, meaning it has tracked the market sideways since August. At $192.28 it sits 85.7% of the way through its 52-week range of $61.50 to $224.31, having stalled below the $224.31 high, a classic consolidation pattern after a parabolic run.
RVMD Technical Analysis
RVMD is in a powerful, sustained uptrend, with the stock up 213.26% over the trailing year and 143.33% year-to-date, dramatically outperforming the S&P 500's 9.59% and 7.83% respective gains. At the current price of $192.28, the stock sits approximately 85.7% of the way through its 52-week range of $61.50 to $224.31 — near the upper quartile but not at the highs, implying strong momentum that has cooled modestly from its peak rather than a fully extended breakout. This positioning suggests the market has already priced in substantial good news (FDA approval, launch traction), leaving the stock vulnerable to profit-taking on any execution stumble while still retaining structural bid support from the secular oncology narrative. Recent momentum has decelerated sharply: the stock is down 4.28% over the past month and 6.27% over three months, a stark divergence from the +213% one-year trend, signaling mean reversion and consolidation after the parabolic run. Notably, the 1-month relative strength of 0.71 versus SPY (which fell 4.99%) shows RVMD slightly outperforming a weak tape, and the 3-month relative strength of -1.36 indicates it has essentially tracked the market sideways since August. The most recent session delivered an 8.24% single-day surge from $177.65 to $192.28 on elevated volume of roughly 4.5 million shares, likely tied to the Q3 earnings beat and Rasonque uptake commentary — a bullish reversal signal after the October pullback to $177.96. Key technical support rests at the 52-week low of $61.50 (a catastrophic breakdown level, far below current trading) with nearer-term support around the October swing low of $177.96 and the $180 area; resistance sits at the 52-week high of $224.31, and a breakout above that level would confirm resumption of the primary uptrend and likely trigger momentum-chasing flows. A beta of 1.431 means the stock is roughly 43% more volatile than the market, and a max drawdown of -24.95% over the period underscores that position sizing must account for sharp 20%+ air pockets — this is a high-beta, event-driven biotech where single-day moves of 8% are routine.
Beta
1.43
1.43x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$64-$224
Price range past year
Annual Return
+182.0%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | -6.8% | -2.4% |
| 3m | -10.5% | -2.3% |
| 6m | +24.1% | +2.8% |
| 1y | +182.0% | +11.3% |
| ytd | +128.7% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revenue has inflected from effectively zero to a commercial ramp: Q3 2026 (quarter ended September 30) delivered $197.56 million in product revenue versus $0 in each of Q1 and Q2 2026 and $0 across all of 2025, reflecting the first full quarter of Rasonque commercialization following FDA approval. This is a genuine launch inflection rather than organic growth, and the sequential jump from zero makes traditional YoY comparisons meaningless — the relevant question is launch trajectory, and the Q3 beat on both earnings and sales with "encouraging Rasonque uptake" suggests the ramp is tracking ahead of expectations. The revenue segment data confirms 100% of revenue is product-based ($197.56 million), with no collaboration or licensing contribution, meaning the entire top line now hinges on commercial execution of a single asset. Profitability remains deeply negative despite the revenue inflection: Q3 net income was -$407.46 million with a net margin of -206.2%, and while gross margin is a striking 99.83% (typical of branded oncology drugs with negligible COGS of just $327,000), operating expenses of $570.38 million — including $417.09 million in R&D and $153.29 million in G&A — swamp gross profit. The loss trajectory is widening, not narrowing: net loss expanded from -$305.21 million in Q3 2025 to -$407.46 million in Q3 2026, and EBITDA deteriorated from -$289.44 million to -$373.05 million over the same period, as commercialization spend and pipeline investment scale up. Balance sheet strength is the company's key asset: debt-to-equity is just 0.097, the current ratio is a robust 7.14, and the company raised roughly $2.2 billion in concurrent upsized offerings in April 2026 (with $1.69 billion in common stock issued in Q2 alone), leaving cash of $631.74 million at Q3 end plus substantial investment securities. However, cash burn is severe — trailing twelve-month free cash flow is -$1.44 billion and Q3 operating cash flow was -$415.65 million — meaning the company is consuming roughly $1.4 billion annually and will need either accelerating product revenue or further capital raises to sustain operations. ROE of -69.35% and ROA of -32.13% reflect the pre-profit, cash-consuming nature of the business; the investment case rests entirely on whether Rasonque's revenue ramp can outpace the burn before dilution becomes punitive.
Quarterly Revenue
$197559000.0B
2026-09
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
99.8%
Latest Quarter
Free Cash Flow
$-1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Because net income is deeply negative (-$407.46 million in Q3, TTM EPS of -$0.07 on a per-share basis but -$1.90 diluted quarterly), the PE ratio is not meaningful — trailing PE of -13.39 and forward PE of -44.37 are artifacts of losses, not valuation signals. I therefore lead with the price-to-sales and EV/Sales metrics: the trailing PS ratio is reported as 0 (reflecting the absence of prior-year revenue), but EV/Sales stands at 198.16x and the historical Q3 PS ratio is 223.32x — extraordinarily high multiples that only make sense if one annualizes the nascent revenue ramp. The forward-looking picture is more instructive: consensus estimated revenue averages $8.47 billion (range $4.31 billion to $16.79 billion) and estimated EPS averages $15.77 (range $5.72 to $35.92), implying the market expects Rasonque to scale into a multi-billion-dollar franchise within a few years — the gap between trailing and forward figures is enormous and reflects the market pricing in a successful, large-scale launch. Peer comparison is constrained by the absence of a formal industry-average multiple in the provided valuation data, but contextually, commercial-stage oncology companies with blockbuster launches typically trade at 8-15x forward sales; RVMD's EV/Sales of 198x on trailing revenue is a massive premium that can only be justified by the forward revenue trajectory implied by consensus. Against its own history, the stock's PB ratio has expanded dramatically — from 3.24x at year-end 2024 to 9.28x at year-end 2025 to 18.37x in Q3 2026 — placing it at the very top of its historical valuation band, a clear signal that the market is pricing in highly optimistic expectations and that multiple compression risk is elevated if launch metrics disappoint. The negative PEG ratio of -0.20 and negative price-to-free-cash-flow of -16.87 are not actionable valuation tools given the loss-making profile; investors should anchor on forward revenue and peak-sales estimates rather than trailing multiples.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by cash consumption and single-asset dependence. Trailing twelve-month free cash flow is -$1.44 billion and Q3 operating cash flow was -$415.65 million, so the company burns roughly $1.4 billion a year while net loss widened to -$407.46 million from -$305.21 million a year earlier. With 100% of the $197.56 million Q3 revenue coming from Rasonque and no collaboration or licensing income, the entire top line hinges on one drug's launch curve; any label restriction, safety signal, or reimbursement friction would hit revenue directly. The $2.2 billion April raise and $631.74 million cash balance provide runway, but continued dilution (shares up ~13.6% in Q2 alone) remains a structural drag if burn persists ahead of revenue scale. Market and competitive risks center on valuation compression and moat durability. At 198.16x EV/Sales and 18.37x book, RVMD trades at a massive premium to the 8-15x forward sales typical of commercial oncology peers, and its PB has tripled from 3.24x at year-end 2024, so any deceleration in launch metrics could trigger sharp multiple compression. The beta of 1.431 means the stock is roughly 43% more volatile than the market, amplifying drawdowns in risk-off tapes, and the 3-month relative strength of -1.36 shows it has already stalled since August. Larger oncology competitors with established commercial infrastructure could erode Rasonque's first-in-class advantage, and the wide $159 analyst target spread ($179 to $338) underscores how much the outcome depends on competitive dynamics and pipeline readouts. The worst-case scenario is a launch deceleration combined with a competitive or safety setback that forces the market to re-rate the stock toward peer multiples. A retest of the October swing low of $177.96 would be a modest -7.4% from $192.28, but a fuller de-rating toward the 52-week low of $61.50 would represent roughly -68%, and the stock's observed max drawdown of -24.95% shows 20%+ air pockets are routine. A realistic adverse case of -25% to -35% (roughly $125 to $144) would follow a Q4 launch miss plus a pipeline disappointment, while the analyst low target of $179.00 caps the near-term downside at about -7% if the Street merely trims estimates.
FAQ
The most severe risk is single-asset concentration: 100% of the $197.56 million in Q3 revenue is Rasonque product sales with no collaboration or licensing cushion, so a safety signal, label restriction, or reimbursement setback hits the entire top line at once. Second is cash burn and dilution — trailing free cash flow of -$1.44 billion, Q3 operating cash flow of -$415.65 million, and a net loss that widened to -$407.46 million from -$305.21 million a year earlier mean another raise is plausible, and shares already rose roughly 13.6% in Q2 alone from the $2.2 billion April offering. Third is valuation compression: at 198.16x EV/Sales and 18.37x book, any deceleration in launch metrics could force a sharp re-rating toward peer multiples, amplified by a 1.431 beta that makes the stock about 43% more volatile than the market. Fourth is competitive and pipeline risk — larger oncology players with established commercial infrastructure could erode the first-in-class moat, and the $159 analyst target spread ($179 to $338) shows how much the outcome hinges on readouts in colorectal and lung cancer. Ranked by severity: concentration first, valuation second, dilution third, competition fourth.
The scenario framework assigns a 55% probability to the base case of $240 to $280, in which Rasonque revenue grows sequentially each quarter without a blowout, gross margin holds near 99.83%, and the stock grinds toward the $261.47 analyst average as forward estimates are validated — range-bound between the $177.96 October low and the $224.31 high before breaking higher late in the period. The 25% bull case targets $300 to $338, requiring Q4 2026 and Q1 2027 beats, pipeline expansion into colorectal and lung, and estimate revisions lifting forward revenue above the $8.47 billion consensus. The 20% bear case targets $140 to $179, driven by a Q4 revenue decline below the $197.56 million base, competitive RAS(ON) data, a safety or label issue, or another dilutive raise. The base case is most likely, and its key assumption is simply that the launch keeps compounding without a material miss. Note that even the bear case's mild end ($179.00) sits only about 7% below the current price, which is why the risk/reward skews favorably despite the rich multiple.
The answer depends entirely on which lens you use, and the gap between them is the heart of the debate. On trailing metrics RVMD is extremely expensive: EV/Sales of 198.16x, a Q3 PS ratio of 223.32x, and a PB ratio that has climbed from 3.24x at year-end 2024 to 9.28x at year-end 2025 to 18.37x in Q3 2026 — the top of its historical band and far above the 8-15x forward sales typical of commercial oncology peers. On forward consensus the picture softens considerably: analysts model $8.47 billion in average revenue (range $4.31 billion to $16.79 billion) and $15.77 in EPS, which against a $15.1 billion market cap implies the market is paying a modest multiple of forward sales for a franchise pegged near $11.5 billion in peak sales. In other words, the market is not paying for today's $197.56 million quarter — it is paying for a successful multi-year launch, and the valuation implies expectations of near-flawless execution. Verdict: overvalued on trailing multiples, arguably fairly valued to modestly undervalued on forward consensus, with little margin of safety if the ramp decelerates.
On risk/reward, RVMD offers roughly +36% to the $261.47 average analyst target against a downside that even the most cautious analyst caps near $179.00, only about 7% below the $192.28 price — an asymmetry that favors buyers, but only at the right entry. The quality of the underlying business is not in question: $197.56 million of first-quarter Rasonque revenue at a 99.83% gross margin, a 7.14 current ratio, and 24 Buy ratings versus a single Hold support the bull case. The catch is that 198.16x trailing EV/Sales and 18.37x book already discount a great deal of that success, and the stock has stalled (-4.28% over one month, -6.27% over three months) below its $224.31 high after a +213.26% year. It is therefore a reasonable buy for growth-oriented investors with a multi-year horizon who size the position for a 1.431 beta and a -24.95% max drawdown, ideally accumulating on pullbacks toward the $177.96 October low. It is a poor buy for anyone seeking income (zero dividend), near-term earnings support (net margin -206.2%), or capital preservation.
RVMD is fundamentally a long-term holding, but one that requires short-term tolerance. The thesis depends on a multi-year commercial ramp toward ~$11.5 billion in peak sales and pipeline expansion beyond pancreatic cancer, which will not be resolved in a quarter or two — yet the stock's 1.431 beta, -24.95% max drawdown, and routine 8% single-day moves (the most recent session jumped 8.24% from $177.65 to $192.28) make it hostile to short-term traders without strict risk controls. There is no dividend (payout ratio 0) and no earnings support (net margin -206.2%), so total return depends entirely on capital appreciation and estimate revisions. A minimum holding period of 18 to 24 months is appropriate, spanning at least four to six quarterly prints so the launch curve and pipeline readouts can be assessed. Short-term traders could trade the $177.96 support and $224.31 resistance range, but position sizing should assume 20%+ air pockets are routine.